Literature DB >> 9811893

The BRCA2 gene product functionally interacts with p53 and RAD51.

L Y Marmorstein1, T Ouchi, S A Aaronson.   

Abstract

Germ-line mutations in the human BRCA2 gene confer susceptibility to breast cancer. Efforts to elucidate its function have revealed a putative transcriptional activation domain and in vitro interaction with the DNA repair protein RAD51. Other studies have indicated that RAD51 physically associates with the p53 tumor suppressor protein. Here we show that the BRCA2 gene product is a 460-kDa nuclear phosphoprotein, which forms in vivo complexes with both p53 and RAD51. Moreover, exogenous BRCA2 expression in cancer cells inhibits p53's transcriptional activity, and RAD51 coexpression enhances BRCA2's inhibitory effects. These findings demonstrate that BRCA2 physically and functionally interacts with two key components of cell cycle control and DNA repair pathways. Thus, BRCA2 likely participates with p53 and RAD51 in maintaining genome integrity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811893      PMCID: PMC24938          DOI: 10.1073/pnas.95.23.13869

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.

Authors:  R Hakem; J L de la Pompa; A Elia; J Potter; T W Mak
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

2.  The BRC repeats are conserved in mammalian BRCA2 proteins.

Authors:  G Bignell; G Micklem; M R Stratton; A Ashworth; R Wooster
Journal:  Hum Mol Genet       Date:  1997-01       Impact factor: 6.150

3.  Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells.

Authors:  J M Gudas; T Li; H Nguyen; D Jensen; F J Rauscher; K H Cowan
Journal:  Cell Growth Differ       Date:  1996-06

4.  The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment.

Authors:  P L Chen; C F Chen; Y Chen; J Xiao; Z D Sharp; W H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

5.  RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein.

Authors:  R Mizuta; J M LaSalle; H L Cheng; A Shinohara; H Ogawa; N Copeland; N A Jenkins; M Lalande; F W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

6.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

7.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2.

Authors:  S K Sharan; M Morimatsu; U Albrecht; D S Lim; E Regel; C Dinh; A Sands; G Eichele; P Hasty; A Bradley
Journal:  Nature       Date:  1997-04-24       Impact factor: 49.962

8.  Mutations of the BRCA2 gene in ovarian carcinomas.

Authors:  H Takahashi; H C Chiu; C A Bandera; K Behbakht; P C Liu; F J Couch; B L Weber; V A LiVolsi; M Furusato; B A Rebane; A Cardonick; I Benjamin; M A Morgan; S A King; J J Mikuta; S C Rubin; J Boyd
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

9.  A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53.

Authors:  D S Lim; P Hasty
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

10.  BRCA2 mutations in primary breast and ovarian cancers.

Authors:  J M Lancaster; R Wooster; J Mangion; C M Phelan; C Cochran; C Gumbs; S Seal; R Barfoot; N Collins; G Bignell; S Patel; R Hamoudi; C Larsson; R W Wiseman; A Berchuck; J D Iglehart; J R Marks; A Ashworth; M R Stratton; P A Futreal
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

View more
  66 in total

1.  Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.

Authors:  B H Spain; C J Larson; L S Shihabuddin; F H Gage; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Characterization of mammalian RAD51 double strand break repair using non-lethal dominant-negative forms.

Authors:  S Lambert; B S Lopez
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

3.  Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium.

Authors:  A D Marmorstein; L Y Marmorstein; M Rayborn; X Wang; J G Hollyfield; K Petrukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

4.  Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining.

Authors:  F Xia; D G Taghian; J S DeFrank; Z C Zeng; H Willers; G Iliakis; S N Powell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

5.  Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndrome.

Authors:  Luciana Nogueira de Sousa Andrade; Jason L Nathanson; Gene W Yeo; Carlos Frederico Martins Menck; Alysson Renato Muotri
Journal:  Hum Mol Genet       Date:  2012-06-01       Impact factor: 6.150

6.  Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2.

Authors:  Sridharan Rajagopalan; Antonina Andreeva; Trevor J Rutherford; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

7.  A molecular portrait of Arabidopsis meiosis.

Authors:  Hong Ma
Journal:  Arabidopsis Book       Date:  2006-06-06

8.  IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.

Authors:  Silvia Maifrede; Kayla Martin; Paulina Podszywalow-Bartnicka; Katherine Sullivan-Reed; Samantha K Langer; Reza Nejati; Yashodhara Dasgupta; Michael Hulse; Daniel Gritsyuk; Margaret Nieborowska-Skorska; Lena N Lupey-Green; Huaqing Zhao; Katarzyna Piwocka; Mariusz A Wasik; Italo Tempera; Tomasz Skorski
Journal:  Mol Cancer Res       Date:  2017-06-20       Impact factor: 5.852

9.  DNA substrate dependence of p53-mediated regulation of double-strand break repair.

Authors:  Nuray Akyüz; Gisa S Boehden; Silke Süsse; Andreas Rimek; Ute Preuss; Karl-Heinz Scheidtmann; Lisa Wiesmüller
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

10.  Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration.

Authors:  Lihua Y Marmorstein; Francis L Munier; Yvan Arsenijevic; Daniel F Schorderet; Precious J McLaughlin; Daniel Chung; Elias Traboulsi; Alan D Marmorstein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.